Prediction of 3D grinding temperature field based on meshless method considering infinite element

© 2018, Springer-Verlag London Ltd., part of Springer Nature. A three-dimensional numerical model to calculate the grinding temperature field distribution is presented. The finite block method, which is developed from meshless method, is used to deal with the stationary and the transient heat conduction problems in this paper. The influences of workpiece feed velocity, cooling coefficient, and the depth of cut on temperature distribution are considered. The model with temperature-dependent thermal conductivity and specific heat is presented. The Lagrange partial differential matrix from the heat transfer governing equation is obtained by using Lagrange series and mapping technique. The grinding wheel-workpiece contact area is assumed as a moving distributed square heat source. The Laplace transformation method and Durbin’s inverse technique are employed in the transient heat conduction analysis. The results of the developed model are compared with others’ finite element method solutions and analytical solutions where a good agreement is demonstrated. And the finite block method was proved a better convergence and accuracy than finite element method by comparing the ABAQUS results. In addition, the three-dimensional infinite element is introduced to perform the thermal analysis, and there is a great of advantages in the simulation of large boundary problems.The work was funded by China Scholarship Council, the Fundamental Research Funds for the Central Universities (N160306006), National Natural Science Foundation of China (51275084), and Science and technology project of Shenyang (18006001)

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Multi-messenger observations of a binary neutron star merger

On 2017 August 17 a binary neutron star coalescence candidate (later designated GW170817) with merger time 12:41:04 UTC was observed through gravitational waves by the Advanced LIGO and Advanced Virgo detectors. The Fermi Gamma-ray Burst Monitor independently detected a gamma-ray burst (GRB 170817A) with a time delay of ~1.7 s with respect to the merger time. From the gravitational-wave signal, the source was initially localized to a sky region of 31 deg2 at a luminosity distance of 40+8-8 Mpc and with component masses consistent with neutron stars. The component masses were later measured to be in the range 0.86 to 2.26 Mo. An extensive observing campaign was launched across the electromagnetic spectrum leading to the discovery of a bright optical transient (SSS17a, now with the IAU identification of AT 2017gfo) in NGC 4993 (at ~40 Mpc) less than 11 hours after the merger by the One- Meter, Two Hemisphere (1M2H) team using the 1 m Swope Telescope. The optical transient was independently detected by multiple teams within an hour. Subsequent observations targeted the object and its environment. Early ultraviolet observations revealed a blue transient that faded within 48 hours. Optical and infrared observations showed a redward evolution over ~10 days. Following early non-detections, X-ray and radio emission were discovered at the transient’s position ~9 and ~16 days, respectively, after the merger. Both the X-ray and radio emission likely arise from a physical process that is distinct from the one that generates the UV/optical/near-infrared emission. No ultra-high-energy gamma-rays and no neutrino candidates consistent with the source were found in follow-up searches. These observations support the hypothesis that GW170817 was produced by the merger of two neutron stars in NGC4993 followed by a short gamma-ray burst (GRB 170817A) and a kilonova/macronova powered by the radioactive decay of r-process nuclei synthesized in the ejecta

Comportamento de cordeiros em pastejo de azevém (Lolium multiflorum) em diferentes fases fenológicas submetidos à adubação nitrogenada

O objetivo deste trabalho foi avaliar o efeito de nitrogênio (N) em pastagem de azevém (Lolium multiflorum Lam.), manejada à mesma altura em pastejo contínuo, sobre o comportamento ingestivo de cordeiros de corte. Utilizaram-se o azevém com quatro doses de N, empregando-se ureia comercial (45% de N) com aplicação única, sendo: 0 kg/ha de N; 75 kg/ha de N; 150 kg/ha de N; e 225 kg/ha de N. O período de avaliação foi de 63 dias, dividido em três períodos de 21, que corresponderam aos estágios de desenvolvimento das plantas desde a fase vegetativa até o florescimento. Em cada período os dias foram divididos em três turnos de avaliação comportamental: manhã (6:30 às 10:30), meio-dia (10:31 às 14:30) e tarde (14:31 às 18:30). Na análise dos períodos, os animais diminuíram a atividade de ócio em 0,3 min a cada dia de avanço no ciclo da pastagem, independentemente do turno de avaliação. Já para o consumo de água, não houve diferença entre as fases fenológicas (média de 1,8 min por dia). Os cordeiros reduziram o tempo de ruminação em 0,612; 0,660; e 0,060 min a cada dia de utilização da pastagem nos turnos da manhã (6 : 30 - 10 : 30), meio-dia (10:31 -14:30) e tarde (14:31 - 18:30), respectivamente, ao passo que para o pastejo os tempos destinados a essa atividade aumentaram 0,726; 1,104; e 0,354 min, respectivamente. Com relação às doses de N, não houve interferência (P > 0,05) sobre as atividades de ruminação (126,6 min) e consumo de água (10,5 min). Observou-se comportamento linear crescente (P < 0,05) para ócio em 0,108 min e decrescente para pastejo em 0,198 min para cada kg de N aplicado na pastagem. O estágio fenológico do azevém influenciou as atividades comportamentais dos cordeiros

Co-transcriptional Analysis of Self-Cleaving Ribozymes and Their Ligand Dependence.

Self-cleaving ribozymes are RNA molecules that catalyze a site-specific self-scission reaction. Analysis of self-cleavage is a crucial aspect of the biochemical study and understanding of these molecules. Here we describe a co-transcriptional assay that allows the analysis of self-cleaving ribozymes in different reaction conditions and in the presence of desired ligands and/or cofactors. Utilizing a standard T7 RNA polymerase in vitro transcription system under limiting Mg2+ concentration, followed by a 25-fold dilution of the reaction in desired conditions of self-cleavage (buffer, ions, ligands, pH, temperature, etc.) to halt the synthesis of new RNA molecules, allows the study of self-scission of these molecules without the need for purification or additional preparation steps, such as refolding procedures. Furthermore, because the transcripts are not denatured, this assay likely yields RNAs in conformations relevant to co-transcriptionally folded species in vivo